BTIG analyst Mark Massaro raised the firm’s price target on GeneDx (WGS) to $125 from $100 and keeps a Buy rating on the shares. The company reported a strong bounce-back in Q2, driving a big $17M beat on the top line, along with a strong gross margin beat, and there is more runway ahead, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx Holdings Reports Strong Q2 2025 Results
- GeneDx Holdings: Strong Growth Prospects and Expansion Opportunities Justify Buy Rating
- GeneDx raises 2025 revenue view to $400M-$415M from $360M-$375M
- GeneDx reports Q2 adjusted EPS 50c, consensus 11c
- GeneDx Holdings: Strong Market Position and Growth Potential in Rare Disease Testing